| Variables . | Level . | High bleeding risk (n = 1826) . | Non-high bleeding risk (n = 3706) . |
|---|---|---|---|
| Sex, n (%) | Male | 1128 (61.8) | 3030 (81.8) |
| Female | 698 (38.2) | 676 (18.2) | |
| Age, years | Median (IQR) | 75 (67–81) | 57 (51–64) |
| Weight, kg | Mean (SD) | 75.7 (16.4) | 86.3 (16.5) |
| Comorbidities | |||
| Hypertension | n (%) | 1036 (56.7) | 1204 (32.5) |
| Hypercholesterolaemia | 696 (38.1) | 1007 (27.2) | |
| Diabetes | 305 (16.7) | 449 (12.1) | |
| Heart failure | 295 (16.2) | 283 (7.6) | |
| Cardiac arrhythmia | 456 (25.0) | 459 (12.4) | |
| Chronic renal failure | 150 (8.2) | 55 (1.5) | |
| Bleeding events | 613 (33.6) | - | |
| Peptic ulcer | 111 (6.1) | 50 (1.3) | |
| Cancer | 322 (17.6) | 213 (5.7) | |
| Stroke | 147 (8.1) | 97 (2.6) | |
| Prior drug use | |||
| Acetylsalicylic acid | n (%) | 536 (29.4) | 504 (13.6) |
| Anticoagulants | 133 (7.3) | 68 (1.8) | |
| Any P2Y12 inhibitor | 141 (7.7) | 124 (3.3) | |
| Proton-pump inhibitors | 510 (27.9) | 598 (16.1) | |
| NSAID | 412 (22.6) | 868 (23.4) | |
| Oral steroids | 165 (9.0) | 136 (3.7) | |
| Blood levels | |||
| Creatinine (µmol/L) | Median (IQR) | 91 (74–116) | 74 (64–85) |
| Creatinine clearance (mL/min) | 60 (46–76) | 100 (93–100) | |
| Leucocytes (× 109/L) | 12.1 (9.4–16.0) | 11.1 (8.9–14.0) | |
| Haemoglobin (mmol/L) | 8.1 (7.2–8.8) | 8.8 (8.3–9.3) | |
| Thrombocytes (× 109/L) | 238 (194–289) | 242 (205–284) | |
| Percutaneous coronary intervention (PCI) | |||
| Ventricular fibrillation and/or pulseless ventricular tachycardia before PCI | n (%) | 257 (14.1) | 384 (10.4) |
| Minutes from symptoms to PCI | Median (IQR) | 189 (129–292) | 166 (120–266) |
| Left ventricular ejection fraction (LVEF), n (%) | ≤35% | 250 (35.4) | 247 (22.4) |
| >35% | 457 (64.6) | 856 (77.6) | |
| Killip class, n (%) | >II | 113 (6.5) | 58 (1.6) |
| I–II | 1637 (93.5) | 3515 (98.4) | |
| Infarct location, n (%) | Anterior | 763 (45.6) | 1532 (44.2) |
| Non-anterior | 911 (54.4) | 1935 (55.8) | |
| Culprit, n (%) | LM/LAD | 829 (45.7) | 1627 (44.2) |
| RCA | 734 (40.5) | 1472 (39.9) | |
| CX | 251 (13.8) | 586 (15.9) | |
| Pre-TIMI, n (%) | 0–I | 1149 (63.8) | 2322 (63.4) |
| II–III | 653 (36.2) | 1338 (36.6) | |
| Post-TIMI, n (%) | 0–I | 61 (3.4) | 70 (1.9) |
| II–III | 1735 (96.6) | 3581 (98.1) | |
| Intervention, n (%) | Drug eluting stent | 1230 (68.3) | 2753 (75.2) |
| Bare metal stent | 115 (6.4) | 137 (3.7) | |
| Stent unknown | 48 (2.7) | 113 (3.1) | |
| Balloon angioplasty only | 407 (22.6) | 657 (18.0) | |
| Lesions, n (%) | 0 lesions | 4 (0.2) | 10 (0.3) |
| 1 lesion | 1466 (80.8) | 3125 (84.7) | |
| ≥2 lesions | 345 (19.0) | 555 (15.0) | |
| Implanted stents, n (%) | None | 418 (23.2) | 673 (18.4) |
| 1 stent | 1165 (64.8) | 2515 (68.8) | |
| ≥2 stents | 215 (12.0) | 467 (12.8) | |
| Revascularization degree according to the operator, n (%) | Complete | 1019 (56.6) | 2360 (64.5) |
| Incomplete–deferred | 426 (23.6) | 869 (23.7) | |
| Incomplete–finished | 357 (19.8) | 430 (11.8) | |
| Variables . | Level . | High bleeding risk (n = 1826) . | Non-high bleeding risk (n = 3706) . |
|---|---|---|---|
| Sex, n (%) | Male | 1128 (61.8) | 3030 (81.8) |
| Female | 698 (38.2) | 676 (18.2) | |
| Age, years | Median (IQR) | 75 (67–81) | 57 (51–64) |
| Weight, kg | Mean (SD) | 75.7 (16.4) | 86.3 (16.5) |
| Comorbidities | |||
| Hypertension | n (%) | 1036 (56.7) | 1204 (32.5) |
| Hypercholesterolaemia | 696 (38.1) | 1007 (27.2) | |
| Diabetes | 305 (16.7) | 449 (12.1) | |
| Heart failure | 295 (16.2) | 283 (7.6) | |
| Cardiac arrhythmia | 456 (25.0) | 459 (12.4) | |
| Chronic renal failure | 150 (8.2) | 55 (1.5) | |
| Bleeding events | 613 (33.6) | - | |
| Peptic ulcer | 111 (6.1) | 50 (1.3) | |
| Cancer | 322 (17.6) | 213 (5.7) | |
| Stroke | 147 (8.1) | 97 (2.6) | |
| Prior drug use | |||
| Acetylsalicylic acid | n (%) | 536 (29.4) | 504 (13.6) |
| Anticoagulants | 133 (7.3) | 68 (1.8) | |
| Any P2Y12 inhibitor | 141 (7.7) | 124 (3.3) | |
| Proton-pump inhibitors | 510 (27.9) | 598 (16.1) | |
| NSAID | 412 (22.6) | 868 (23.4) | |
| Oral steroids | 165 (9.0) | 136 (3.7) | |
| Blood levels | |||
| Creatinine (µmol/L) | Median (IQR) | 91 (74–116) | 74 (64–85) |
| Creatinine clearance (mL/min) | 60 (46–76) | 100 (93–100) | |
| Leucocytes (× 109/L) | 12.1 (9.4–16.0) | 11.1 (8.9–14.0) | |
| Haemoglobin (mmol/L) | 8.1 (7.2–8.8) | 8.8 (8.3–9.3) | |
| Thrombocytes (× 109/L) | 238 (194–289) | 242 (205–284) | |
| Percutaneous coronary intervention (PCI) | |||
| Ventricular fibrillation and/or pulseless ventricular tachycardia before PCI | n (%) | 257 (14.1) | 384 (10.4) |
| Minutes from symptoms to PCI | Median (IQR) | 189 (129–292) | 166 (120–266) |
| Left ventricular ejection fraction (LVEF), n (%) | ≤35% | 250 (35.4) | 247 (22.4) |
| >35% | 457 (64.6) | 856 (77.6) | |
| Killip class, n (%) | >II | 113 (6.5) | 58 (1.6) |
| I–II | 1637 (93.5) | 3515 (98.4) | |
| Infarct location, n (%) | Anterior | 763 (45.6) | 1532 (44.2) |
| Non-anterior | 911 (54.4) | 1935 (55.8) | |
| Culprit, n (%) | LM/LAD | 829 (45.7) | 1627 (44.2) |
| RCA | 734 (40.5) | 1472 (39.9) | |
| CX | 251 (13.8) | 586 (15.9) | |
| Pre-TIMI, n (%) | 0–I | 1149 (63.8) | 2322 (63.4) |
| II–III | 653 (36.2) | 1338 (36.6) | |
| Post-TIMI, n (%) | 0–I | 61 (3.4) | 70 (1.9) |
| II–III | 1735 (96.6) | 3581 (98.1) | |
| Intervention, n (%) | Drug eluting stent | 1230 (68.3) | 2753 (75.2) |
| Bare metal stent | 115 (6.4) | 137 (3.7) | |
| Stent unknown | 48 (2.7) | 113 (3.1) | |
| Balloon angioplasty only | 407 (22.6) | 657 (18.0) | |
| Lesions, n (%) | 0 lesions | 4 (0.2) | 10 (0.3) |
| 1 lesion | 1466 (80.8) | 3125 (84.7) | |
| ≥2 lesions | 345 (19.0) | 555 (15.0) | |
| Implanted stents, n (%) | None | 418 (23.2) | 673 (18.4) |
| 1 stent | 1165 (64.8) | 2515 (68.8) | |
| ≥2 stents | 215 (12.0) | 467 (12.8) | |
| Revascularization degree according to the operator, n (%) | Complete | 1019 (56.6) | 2360 (64.5) |
| Incomplete–deferred | 426 (23.6) | 869 (23.7) | |
| Incomplete–finished | 357 (19.8) | 430 (11.8) | |
Missing: Leucocytes (19%), LVEF (67%), infarct location (7%).
CX, circumflex coronary artery; LAD, left anterior descending coronary artery; LM, left main coronary artery; NSAID, non-steroidal anti-inflammatory drugs; RCA, right coronary artery; TIMI, thrombolysis in myocardial infarction.
| Variables . | Level . | High bleeding risk (n = 1826) . | Non-high bleeding risk (n = 3706) . |
|---|---|---|---|
| Sex, n (%) | Male | 1128 (61.8) | 3030 (81.8) |
| Female | 698 (38.2) | 676 (18.2) | |
| Age, years | Median (IQR) | 75 (67–81) | 57 (51–64) |
| Weight, kg | Mean (SD) | 75.7 (16.4) | 86.3 (16.5) |
| Comorbidities | |||
| Hypertension | n (%) | 1036 (56.7) | 1204 (32.5) |
| Hypercholesterolaemia | 696 (38.1) | 1007 (27.2) | |
| Diabetes | 305 (16.7) | 449 (12.1) | |
| Heart failure | 295 (16.2) | 283 (7.6) | |
| Cardiac arrhythmia | 456 (25.0) | 459 (12.4) | |
| Chronic renal failure | 150 (8.2) | 55 (1.5) | |
| Bleeding events | 613 (33.6) | - | |
| Peptic ulcer | 111 (6.1) | 50 (1.3) | |
| Cancer | 322 (17.6) | 213 (5.7) | |
| Stroke | 147 (8.1) | 97 (2.6) | |
| Prior drug use | |||
| Acetylsalicylic acid | n (%) | 536 (29.4) | 504 (13.6) |
| Anticoagulants | 133 (7.3) | 68 (1.8) | |
| Any P2Y12 inhibitor | 141 (7.7) | 124 (3.3) | |
| Proton-pump inhibitors | 510 (27.9) | 598 (16.1) | |
| NSAID | 412 (22.6) | 868 (23.4) | |
| Oral steroids | 165 (9.0) | 136 (3.7) | |
| Blood levels | |||
| Creatinine (µmol/L) | Median (IQR) | 91 (74–116) | 74 (64–85) |
| Creatinine clearance (mL/min) | 60 (46–76) | 100 (93–100) | |
| Leucocytes (× 109/L) | 12.1 (9.4–16.0) | 11.1 (8.9–14.0) | |
| Haemoglobin (mmol/L) | 8.1 (7.2–8.8) | 8.8 (8.3–9.3) | |
| Thrombocytes (× 109/L) | 238 (194–289) | 242 (205–284) | |
| Percutaneous coronary intervention (PCI) | |||
| Ventricular fibrillation and/or pulseless ventricular tachycardia before PCI | n (%) | 257 (14.1) | 384 (10.4) |
| Minutes from symptoms to PCI | Median (IQR) | 189 (129–292) | 166 (120–266) |
| Left ventricular ejection fraction (LVEF), n (%) | ≤35% | 250 (35.4) | 247 (22.4) |
| >35% | 457 (64.6) | 856 (77.6) | |
| Killip class, n (%) | >II | 113 (6.5) | 58 (1.6) |
| I–II | 1637 (93.5) | 3515 (98.4) | |
| Infarct location, n (%) | Anterior | 763 (45.6) | 1532 (44.2) |
| Non-anterior | 911 (54.4) | 1935 (55.8) | |
| Culprit, n (%) | LM/LAD | 829 (45.7) | 1627 (44.2) |
| RCA | 734 (40.5) | 1472 (39.9) | |
| CX | 251 (13.8) | 586 (15.9) | |
| Pre-TIMI, n (%) | 0–I | 1149 (63.8) | 2322 (63.4) |
| II–III | 653 (36.2) | 1338 (36.6) | |
| Post-TIMI, n (%) | 0–I | 61 (3.4) | 70 (1.9) |
| II–III | 1735 (96.6) | 3581 (98.1) | |
| Intervention, n (%) | Drug eluting stent | 1230 (68.3) | 2753 (75.2) |
| Bare metal stent | 115 (6.4) | 137 (3.7) | |
| Stent unknown | 48 (2.7) | 113 (3.1) | |
| Balloon angioplasty only | 407 (22.6) | 657 (18.0) | |
| Lesions, n (%) | 0 lesions | 4 (0.2) | 10 (0.3) |
| 1 lesion | 1466 (80.8) | 3125 (84.7) | |
| ≥2 lesions | 345 (19.0) | 555 (15.0) | |
| Implanted stents, n (%) | None | 418 (23.2) | 673 (18.4) |
| 1 stent | 1165 (64.8) | 2515 (68.8) | |
| ≥2 stents | 215 (12.0) | 467 (12.8) | |
| Revascularization degree according to the operator, n (%) | Complete | 1019 (56.6) | 2360 (64.5) |
| Incomplete–deferred | 426 (23.6) | 869 (23.7) | |
| Incomplete–finished | 357 (19.8) | 430 (11.8) | |
| Variables . | Level . | High bleeding risk (n = 1826) . | Non-high bleeding risk (n = 3706) . |
|---|---|---|---|
| Sex, n (%) | Male | 1128 (61.8) | 3030 (81.8) |
| Female | 698 (38.2) | 676 (18.2) | |
| Age, years | Median (IQR) | 75 (67–81) | 57 (51–64) |
| Weight, kg | Mean (SD) | 75.7 (16.4) | 86.3 (16.5) |
| Comorbidities | |||
| Hypertension | n (%) | 1036 (56.7) | 1204 (32.5) |
| Hypercholesterolaemia | 696 (38.1) | 1007 (27.2) | |
| Diabetes | 305 (16.7) | 449 (12.1) | |
| Heart failure | 295 (16.2) | 283 (7.6) | |
| Cardiac arrhythmia | 456 (25.0) | 459 (12.4) | |
| Chronic renal failure | 150 (8.2) | 55 (1.5) | |
| Bleeding events | 613 (33.6) | - | |
| Peptic ulcer | 111 (6.1) | 50 (1.3) | |
| Cancer | 322 (17.6) | 213 (5.7) | |
| Stroke | 147 (8.1) | 97 (2.6) | |
| Prior drug use | |||
| Acetylsalicylic acid | n (%) | 536 (29.4) | 504 (13.6) |
| Anticoagulants | 133 (7.3) | 68 (1.8) | |
| Any P2Y12 inhibitor | 141 (7.7) | 124 (3.3) | |
| Proton-pump inhibitors | 510 (27.9) | 598 (16.1) | |
| NSAID | 412 (22.6) | 868 (23.4) | |
| Oral steroids | 165 (9.0) | 136 (3.7) | |
| Blood levels | |||
| Creatinine (µmol/L) | Median (IQR) | 91 (74–116) | 74 (64–85) |
| Creatinine clearance (mL/min) | 60 (46–76) | 100 (93–100) | |
| Leucocytes (× 109/L) | 12.1 (9.4–16.0) | 11.1 (8.9–14.0) | |
| Haemoglobin (mmol/L) | 8.1 (7.2–8.8) | 8.8 (8.3–9.3) | |
| Thrombocytes (× 109/L) | 238 (194–289) | 242 (205–284) | |
| Percutaneous coronary intervention (PCI) | |||
| Ventricular fibrillation and/or pulseless ventricular tachycardia before PCI | n (%) | 257 (14.1) | 384 (10.4) |
| Minutes from symptoms to PCI | Median (IQR) | 189 (129–292) | 166 (120–266) |
| Left ventricular ejection fraction (LVEF), n (%) | ≤35% | 250 (35.4) | 247 (22.4) |
| >35% | 457 (64.6) | 856 (77.6) | |
| Killip class, n (%) | >II | 113 (6.5) | 58 (1.6) |
| I–II | 1637 (93.5) | 3515 (98.4) | |
| Infarct location, n (%) | Anterior | 763 (45.6) | 1532 (44.2) |
| Non-anterior | 911 (54.4) | 1935 (55.8) | |
| Culprit, n (%) | LM/LAD | 829 (45.7) | 1627 (44.2) |
| RCA | 734 (40.5) | 1472 (39.9) | |
| CX | 251 (13.8) | 586 (15.9) | |
| Pre-TIMI, n (%) | 0–I | 1149 (63.8) | 2322 (63.4) |
| II–III | 653 (36.2) | 1338 (36.6) | |
| Post-TIMI, n (%) | 0–I | 61 (3.4) | 70 (1.9) |
| II–III | 1735 (96.6) | 3581 (98.1) | |
| Intervention, n (%) | Drug eluting stent | 1230 (68.3) | 2753 (75.2) |
| Bare metal stent | 115 (6.4) | 137 (3.7) | |
| Stent unknown | 48 (2.7) | 113 (3.1) | |
| Balloon angioplasty only | 407 (22.6) | 657 (18.0) | |
| Lesions, n (%) | 0 lesions | 4 (0.2) | 10 (0.3) |
| 1 lesion | 1466 (80.8) | 3125 (84.7) | |
| ≥2 lesions | 345 (19.0) | 555 (15.0) | |
| Implanted stents, n (%) | None | 418 (23.2) | 673 (18.4) |
| 1 stent | 1165 (64.8) | 2515 (68.8) | |
| ≥2 stents | 215 (12.0) | 467 (12.8) | |
| Revascularization degree according to the operator, n (%) | Complete | 1019 (56.6) | 2360 (64.5) |
| Incomplete–deferred | 426 (23.6) | 869 (23.7) | |
| Incomplete–finished | 357 (19.8) | 430 (11.8) | |
Missing: Leucocytes (19%), LVEF (67%), infarct location (7%).
CX, circumflex coronary artery; LAD, left anterior descending coronary artery; LM, left main coronary artery; NSAID, non-steroidal anti-inflammatory drugs; RCA, right coronary artery; TIMI, thrombolysis in myocardial infarction.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
